Glaucoma
| Brand | Generic | Dosing | Amount | Ages | Pregnancy | Mechanism |
|---|---|---|---|---|---|---|
Generic | brimonidine 0.1/0.15/0.2*% | tid | 5/10/15mL | >2 years | B | α-2 agonist ↓ aqueous production ↑ outflow |
Generic | brinzolamide 1% | tid | 5/10/15mL | NA | C | carbonic anhydrase inhibitor ↓ aqueous production |
Generic | brimonidine 0.2% timolol 0.5% | bid | 5/10/15mL | >2 years | C | α-2 agonist β blocker ↓ aqueous production, ↑ outflow |
Generic | dorzolamide 2% timolol 0.5% | bid | 5/10mL | >2 years | C | carbonic anhydrase inhibitor β blocker ↓ aqueous production |
GenericPO | acetazolamide | 500mg po bid | 125/250mg 500mg 'Sequels' | >12 years | C | carbonic anhydrase inhibitor ↓ aqueous production |
Generic | pilocarpine 1/2/4% | qd-qid | 15mL | >2 years | C | cholinergic agonist ↑ outflow |
Generic | bimatoprost 0.01/0.03*% | qhs | 2.5/5/7.5mL | >16 years | C | prostaglandin analogue ↑ outflow |
| netarsudil 0.02% | qhs | 2.5mL | NA | NA | Rho kinase inhibitor ↑ outflow | |
| netarsudil 0.02% latanoprost 0.005% | qhs | 2.5mL | NA | NA | Rho kinase inhibitor prostaglandin analogue ↑ outflow | |
| brimonidine 0.2% brinzolamide 1% | tid | 8mL | >2 years | C | α-2 agonist carbonic anhydrase inhibitor ↓ aqueous production ↑ outflow | |
Generic | timolol maleate 0.25/0.5% | bid | 5/10/15mL | >2 years | C | β blocker ↓ aqueous production |
Generic | travoprost 0.004% | qhs | 2.5/5mL | >16 years | C | prostaglandin analogue ↑ outflow |
Generic | dorzolamide 2% | bid-tid | 5/10mL | >2 years | C | carbonic anhydrase inhibitor ↓ aqueous production |
| latanoprostene bunod 0.024% | qhs | 5mL | >16 years | NA | prostaglandin analogue ↑ outflow | |
Generic | latanoprost 0.005% | qhs | 2.5mL | NA | C | prostaglandin analogue ↑ outflow |
| latanoprost 0.005% (BAK free) | qhs | 2.5mL | NA | C | prostaglandin analogue ↑ outflow | |
| tafluprost 0.0015% | qhs | 30/90 pack | Not Recommended | C | prostaglandin analogue ↑ outflow |